Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases

Sarah Y. Boostrom, David M. Nagorney, John H. Donohue, Scott Harmsen, Kristine Thomsen, Florencia Que, Michael Kendrick, Kaye M. Reid-Lombardo

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Study Aims To determine if neoadjuvant FOLFOX/FOLFIRI is associated with improved disease-free survival (DFS) or overall survival (OS) in patients with colorectal metastases (CRM) to the liver. Methods Ninety-nine patients (from 457 eligible) with CRM that underwent hepatic resection during 2000 to 2005 were included. Group 1 (n=44) patients received neoadjuvant FOLFOX/FOLFIRI, and Group 2 (n=55) did not receive neoadjuvant therapy. Results There were 58% men. The median age for Group 1 was 58 and Group 2, 64 (p=0.03). OS for Group 1 at 1, 3, and 5 years was 93%, 62%, and 51%, respectively, with a median OS of 5.8 years. In Group 2 survival at 1l, 3, and 5 years was 90%,63%, and 45%, respectively, with a median OS of 3.7 years (HR 1.06, p=0.87). The DFS for Group 1 at 1, 3, and 5 years was 51%, 20%, and 20%, with a median DFS of 1.1 years and Group 2 at 1, 3, and 5 years was 58%, 32%, and 32% (median DFS-1.2 years; HR=1.24, p=0.45). Conclusions Neoadjuvant FOLFOX/FOLFIRI was employed more frequently in younger patients with CRM; however, neoadjuvant chemotherapy for CRM was not significantly associated with an increase in OS or DFS, despite additional adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)2003-2010
Number of pages8
JournalJournal of Gastrointestinal Surgery
Volume13
Issue number11
DOIs
StatePublished - Sep 17 2009

Keywords

  • Neoadjuvant therapy. FOLFOX. Hepatectomy. Colorectal cancer metastases. Survival

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Fingerprint Dive into the research topics of 'Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases'. Together they form a unique fingerprint.

  • Cite this

    Boostrom, S. Y., Nagorney, D. M., Donohue, J. H., Harmsen, S., Thomsen, K., Que, F., Kendrick, M., & Reid-Lombardo, K. M. (2009). Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases. Journal of Gastrointestinal Surgery, 13(11), 2003-2010. https://doi.org/10.1007/s11605-009-1007-3